|
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
|
Nov 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
The myelodysplastic syndromes flow cytometric score: a 3-parameter prognostic flow cytometric scoring system
|
Oct 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides
|
Oct 2015
|
Leukemia
|
|
|
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
|
Jan 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes.
|
Jun 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
|
Mar 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML
|
Jul 2017
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
|
Oct 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?
|
Jan 2021
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Effectiveness of azacitidine in higher-risk myelodysplastic syndromes
|
May 2016
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
